Exenatide once weekly: clinical outcomes and patient satisfaction

References

• MokdadAHFordESBowmanBAPrevalence of obesity, diabetes, and obesity-related health risk factorsJ Am Med Assoc20032897679
   PubMed Web of Science ®Google Scholar
• IDFThe Diabetes Atlas IDF [serial online]2006
   Google Scholar
• de GrootMAndersonRFreedlandKEClouseRELustmanPJAssociation of depression and diabetes complications: a meta-analysisPsychosom Med20016361963011485116
   PubMed Web of Science ®Google Scholar
• WanlessDSecuring our future health: taking a long-term view [April 2002] Available from: http://www.hm-treasury.gov.uk/consultations_and_legislation/wanless/consult_wanless_final.cfm. Accessed Feb 12, 2010.
   Google Scholar
• JacobsonAMImpact of improved glycemic control on quality of life in patients with diabetesEndocr Pract20041050250816033724
   PubMedGoogle Scholar
• FacchiniFSHuaNAbbasiFReavenGMInsulin resistance as a predictor of age-related diseasesJ Clin Endocrinol Metab2001863574357811502781
   PubMed Web of Science ®Google Scholar
• StumvollMGoldsteinBJvan HaeftenTWType 2 diabetes: principles of pathogenesis and therapyLancet20053651333134615823385
   PubMed Web of Science ®Google Scholar
• ReavenGMRole of insulin resistance in human diseaseDiabetes198837159516073056758
   PubMed Web of Science ®Google Scholar
• KahnSEHullRLUtzschneiderKMMechanisms linking obesity to insulin resistance and type 2 diabetesNature198844484084617167471
   PubMed Web of Science ®Google Scholar
• KahnSEThe importance of [beta]-cell failure in the development and progression of type 2 diabetesJ Clin Endocrinol Metab2001864047405811549624
   PubMed Web of Science ®Google Scholar
• KahnSEQuantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic functionDiabetes199342166316728405710
   PubMed Web of Science ®Google Scholar
• PerleyMKipnisDMPlasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjectsDiabetes1966158678745957477
   PubMed Web of Science ®Google Scholar
• PolonskyKSGivenBDvan CauterETwenty-four-hour profiles and patterns of insulin secretion in normal and obese subjectsJ Clin Invest1988814424483276730
   PubMed Web of Science ®Google Scholar
• BurcelinRKnaufCCaniPDPancreatic alpha-cell dysfunction in diabetesDiabetes Metab200834Suppl 2S49S5518640586
   PubMed Web of Science ®Google Scholar
• SalvatoreTGiuglianoDPharmacokinetic-pharmacodynamic relationships of AcarboseClin Pharmacokinet199630941068906894
   PubMed Web of Science ®Google Scholar
• DelPSBianchiCMarchettiPBeta-cell function and anti-diabetic pharmacotherapyDiabetes Metab Res Rev20072351852717883249
   PubMed Web of Science ®Google Scholar
• PiyaMKTahraniAABarnettAHLiraglutide: a new option in the management of type 2 diabetesFuture Prescriber20089612
   Google Scholar
• RedekkopWKKoopmanschapMAStolkRPRuttenGEHNiessenLWHealth-related quality of life and treatment satisfaction in Dutch patients with type diabetesDiabetes Care20022545846311874930
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupIntensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• CramerJAA systematic review of adherence with medications for diabetesDiabetes Care2004271218122415111553
   PubMed Web of Science ®Google Scholar
• GlasgowRECompliance to diabetes regimens: conceptualization, complexity, and determinantsCramerJASpilkerBPatient Compliance in Medical Practice and Clinical TrialsNew YorkRaven Press1991209224
   Google Scholar
• PughMJAndersonJPogachLMBerlowitzDRDifferential adoption of pharmacotherapy recommendations for type 2 diabetes by generalists and specialistsMed Care Res Rev20036017820012800683
   PubMed Web of Science ®Google Scholar
• TahraniAAPiyaMKKennedyABarnettAHGlycaemic control in type 2 diabetes: targets and new therapiesPharmacol Ther20102125232836119931305
   PubMed Web of Science ®Google Scholar
• PalalauAITahraniAAPiyaMKBarnettAHDPP-4 inhibitors in clinical practicePostgrad Med200912167010019940419
   PubMed Web of Science ®Google Scholar
• TahraniAAPiyaMKBarnettAHSaxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitusAdv Ther20092624926219330494
   PubMed Web of Science ®Google Scholar
• PetersAIncretin-based therapies: review of current clinical trial dataAm J Med2010123Suppl 3S28S3720206729
   PubMed Web of Science ®Google Scholar
• TahraniAAPiyaMKBarnettAHDrug evaluation: vildagliptin-metformin single-tablet combinationAdv Ther2009226213815419288260
   PubMed Web of Science ®Google Scholar
• AhrenBGut peptides and type 2 diabetes mellitus treatmentCurr Diab Rep2003336537212975025
   PubMedGoogle Scholar
• ElrickHStimmlerLHladCJJrRaiYPlasma insulin response to oral and intravenous glucose administrationJ Clin Endocrinol Metab1964241076108214228531
   PubMed Web of Science ®Google Scholar
• NauckMAHombergerESiegelEGIncretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responsesJ Clin Endocrinol Metab1986634924983522621
   PubMed Web of Science ®Google Scholar
• BrownJCDryburghJRA gastric inhibitory polypeptide. II. The complete amino acid sequenceCan J Biochem1971498678725120249
   PubMedGoogle Scholar
• DupreJRossSAWatsonDBrownJCStimulation of insulin secretion by gastric inhibitory polypeptide in manJ Clin Endocrinol Metab1973378268284749457
   PubMed Web of Science ®Google Scholar
• BaggioLLDruckerDJBiology of incretins: GLP-1 and GIPGastroenterology20071322131215717498508
   PubMed Web of Science ®Google Scholar
• KimWEganJMThe role of incretins in glucose homeostasis and diabetes treatmentPharmacol Rev200860447051219074620
   PubMed Web of Science ®Google Scholar
• DruckerDJPhilippeJMojsovSChickWLHabenerJFGlucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell lineProc Natl Acad Sci U S A198784343434383033647
   PubMed Web of Science ®Google Scholar
• NauckMAHombergerESiegelEGIncretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responsesJ Clin Endocrinol Metab1986634924983522621
   PubMed Web of Science ®Google Scholar
• AhrenBGut peptides and type 2 diabetes mellitus treatmentCurr Diab Rep2003336537212975025
   PubMedGoogle Scholar
• DruckerDJGlucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosisEndocrinology20031445145514814645210
   PubMed Web of Science ®Google Scholar
• Toft-NielsenMBDamholtMBMadsbadSDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patientsJ Clin Endocrinol Metab2001863717372311502801
   PubMed Web of Science ®Google Scholar
• NauckMAKleineNOrskovCHolstJJWillmsBCreutzfeldtWNormalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patientsDiabetologia1993367417448405741
   PubMed Web of Science ®Google Scholar
• GutniakMKLindeBHolstJJEfendicSSubcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDMDiabetes Care199417103910447988303
   PubMed Web of Science ®Google Scholar
• DeaconCFJohnsenAHHolstJJDegradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivoJ Clin Endocrinol Metab1995809529577883856
   PubMed Web of Science ®Google Scholar
• MentleinRDipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptidesRegul Pept19998592410588446
   PubMed Web of Science ®Google Scholar
• BarnettAExenatideExpert Opin Pharmacother200782593260817931093
   PubMed Web of Science ®Google Scholar
• BYETTA prescribing information [article on the Internet]. Available from: http://pi.lilly.com/us/byetta-pi.pdf. Accessed Feb 16, 2010.
   Google Scholar
• TriplittCDeFronzoRAExenatide: first-in-class incretin mimetic for the treatment of type 2 diabetes mellitusExpert Rev Endocrinol Metab20061329341
   PubMedGoogle Scholar
• KoltermanOGKimDDShenLPharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitusAm J Health Syst Pharm20056217318115700891
   PubMed Web of Science ®Google Scholar
• DeFronzoRARatnerREHanJKimDDFinemanMSBaronADEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care2005281092110015855572
   PubMed Web of Science ®Google Scholar
• BarnettAHBurgerJJohnsDTolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonyulurea: a multinational, randomized, open-label, two-period, crossover noninferiority trialClin Ther200729112333234818158075
   PubMed Web of Science ®Google Scholar
• PoonTNelsonPShenLExenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a doseranging studyDiabetes Technol Ther2005746747715929678
   PubMedGoogle Scholar
• KoltermanOGBuseJBFinemanMSSynthetic Exendin-4 (exenatide) significantly reduces post-prandial and fasting plasma glucose in subjects with Type 2 diabetesJ Clin Endocrinol Metab20078873082308912843147
   PubMed Web of Science ®Google Scholar
• EdwardsCMStanleySADavisRExendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteersAm J Physiol Endocrinol Metab20017281E155E161
   Web of Science ®Google Scholar
• Toft-NielsenMBMadsbadSHolstJJContinuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patientsDiabetes Care199972271137114310388979
   PubMed Web of Science ®Google Scholar
• RatnerREMaggsDNielsenLLLong-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitusDiabetes Obes Metab20068441942816776749
   PubMed Web of Science ®Google Scholar
• BuseJBHenryRRHanJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes Care2004272628263515504997
   PubMed Web of Science ®Google Scholar
• KendallDMRiddleMCRosenstockJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDiabetes Care2005281083109115855571
   PubMed Web of Science ®Google Scholar
• RiddleMCHenryRRPoonTHExenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metforminDiabetes Metab Res Rev20062248349116634116
   PubMed Web of Science ®Google Scholar
• KlonoffDCBuseJBNielsenLLExenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurr Med Res Opin20082427528618053320
   PubMed Web of Science ®Google Scholar
• BuseJBKlonoffDCNielsenLLMetabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo controlled trialsClin Ther20072913915317379054
   PubMed Web of Science ®Google Scholar
• FDA prescribing information for exenatide Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021773s012lbl.pdf. Accessed Mar 18, 2010.
   Google Scholar
• MonamiMMarchionniNMannucciEGlucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trialsEur J Endocrinol200916090991719318378
   PubMed Web of Science ®Google Scholar
• DoreDDSeegerJDArnoldCKUse of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburideCurr Med Res Opin2009251019102719278373
   PubMed Web of Science ®Google Scholar
• TracyMAWardKLFirouzabadianLFactors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitroBiomaterials1999201057106210378806
   PubMed Web of Science ®Google Scholar
• KimDMacConellLZhuangDEffects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetesDiabetes Care2007301487149317353504
   PubMed Web of Science ®Google Scholar
• TaylorKKimDNielsenLLAispornaMBaronADFinemanMSDay-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetesHorm Metab Res20053762763216278786
   PubMed Web of Science ®Google Scholar
• IwamotoKNasuRYamamuraASafety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetesEndocr J200956895196219706990
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet20083721240125018782641
   PubMed Web of Science ®Google Scholar
• BuseJBDruckerDJTaylorKDURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeksDiabetes Care20103361255126120215461
   PubMed Web of Science ®Google Scholar
• TrautmannMWilhelmKTaylorKKimTZhuangDPorterLExenatide once-weekly treatment elicits sustained glycaemic control and weight loss over 2 yearsDiabetologia200952Suppl 1S286
   Google Scholar
• KadowakiTNambaMYamamuraASowaHWolkaAMBrodowsRGExenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2diabetesEndocr J20095641542419194050
   PubMed Web of Science ®Google Scholar
• WyshamCBergenstalRYanPMacConellLMalloyJPorterLDURATION-2: exenatide once weekly demonstrated superior glycaemic control and weight reduction compared to sitagliptin or pioglitazone after 26 weeks of treatmentDiabetologia200952Suppl 1S290
   Google Scholar
• BergenstalRWyshamCYanPMacconellLMalloyJPorterLDURATION-2: exenatide once weekly demonstrated superior glycemic control and weight reduction compared to sitagliptin or pioglitazone after 26 weeks of treatmentPresented at ADA 2009San Diego, CA2009
   Google Scholar
• Press Release. Amylin, Lilly and Alkermes companies announce exenatide once weekly provided superior glucose control compared to Lantus in head-to-head DURATION-3 studySan Diego, CAAmylin Pharmaceuticals2009 Available from: http://files.shareholder.com/downloads/LLY/0x0x307776/675c0e3a-b736-4a08-a30c-bab4ec187b39/LLY_News_2009_7_20_Product.pdf. Accessed February 27, 2010.
   Google Scholar
• Current trials involving exenatide LAR Available from: http://clinicaltrials.gov|~http://clinicaltrials.gov/. Accessed Mar 18, 2010.
   Google Scholar
• DiMatteoMRGiordaniPJLepperHSGroghanTWPatient adherence and medical outcomes: a meta-analysisMed Care20024079481112218770
   PubMed Web of Science ®Google Scholar
• BestJHBoyeKSRubinRRCaoDKimTHPeyrotMImproved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice dailyDiabet Med200926772272819573122
   PubMed Web of Science ®Google Scholar
• BestJHYanPMalloyJDURATION 2: weight-related quality of life, psychological well-being, and satisfaction with exenatide once weekly compared to sitagliptin or piaglitazone after 26 weeks of treatmentDiabetologia200952Suppl 1S292
   Google Scholar